Maryland SB969 mandates health insurers to cover long-term antibiotic treatment for Lyme disease and related tick-borne illnesses.
Maryland SB969 requires insurers, nonprofit health service plans, and health maintenance organizations to cover the full length of long-term antibiotic treatment for Lyme disease and related tick-borne illnesses. The bill prohibits these entities from imposing quantitative limits or denying coverage for such treatments. It applies to all policies, contracts, and health benefit plans issued, delivered, or renewed in the state on or after January 1, 2027.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.